Novo Nordisk reports glucose control and weight loss benefits of semaglutide

Novo Nordisk has reported new clinical trial data that demonstrates the benefits of its investigational diabetes therapy semaglutide.

Results from the phase IIIa SUSTAIN 2-4 trials have shown that the drug was associated with greater mean reductions in blood glucose and body weight with compared to sitagliptin, exenatide extended release and insulin glargine U100 in adults with type 2 diabetes.

Study participants came from multiple background oral antidiabetic treatment categories, indicating that the benefits of semaglutide can be experienced regardless of the patient's treatment history.

It was also shown that semaglutide was well tolerated, with a similar safety profile to other GLP-1 receptor agonists.

Vanita Aroda, physician investigator at the MedStar Health Research Institute in Hyattsville, said: "Type 2 diabetes is a complex disease, and as a result many patients are not reaching
their targets on current oral antidiabetic therapy."

Once-weekly semaglutide is currently under review by the US Food and Drug Administration, the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.